Kimberly-Clark said on Monday it will buy Tylenol maker Kenvue KVUE.N in a cash-and-stock deal valued at about $48.7 billion, to create one of the biggest consumer health goods companies in the United States. Shares of Kenvue were up 18% in premarket trading, while Kimberly-Clark‘s shares were down 12.5%. Kenvue has been under a strategic review, leadership shake-up, and mounting ...